Logo image
Back
Effect of dosing interval on pharmacokinetics of fentanyl pectin nasal spray from a crossover study
Journal article   Peer reviewed

Effect of dosing interval on pharmacokinetics of fentanyl pectin nasal spray from a crossover study

Cuiping Chen, Shay Bujanover, Anita Gupta and Chaomei Chen
Journal of opioid management, v 11(2)
Mar 2015
DOI: https://doi.org/10.5055/jom.2015.0263
PMID: 25901479

Abstract

Administration, Intranasal Adolescent Adult Aged Analgesics, Opioid - administration & dosage Analgesics, Opioid - pharmacokinetics Cross-Over Studies Dose-Response Relationship, Drug Drug Administration Schedule Drug Combinations Female Fentanyl - administration & dosage Fentanyl - pharmacokinetics Follow-Up Studies Humans Male Middle Aged Nasal Sprays Pain - drug therapy Pain - metabolism Pectins - administration & dosage Pectins - pharmacokinetics Retrospective Studies Young Adult
To evaluate the effects of different dosing intervals on multiple-dose pharmacokinetics, and safety and tolerability of fentanyl pectin nasal spray (FPNS). This was an open-label study in healthy volunteers. Five FPNS treatments (1 × 100 μg; 2 × 100 μg at 4-, 2-, and 1-hour intervals, and 8 × 100 μg consecutively) were administered to the right nostril, with a ≥ 3-day washout period. Blood samples were collected at predose and up to 1,440 minutes postdose. Plasma fentanyl concentrations were determined. Pharmacokinetic parameters-peak concentration (C(max)), time to C(max) (t(max)), and area under the concentration-time curve (AUC)-were derived using noncompartmental method. For the two-dose regimens, pharmacokinetic parameters were compared between doses using a paired t-test with p < 0.05 as statistically significant. Thirteen subjects were enrolled and 10 completed the study. Median tmax was 10-15 minutes across five regimens. Cmax post the second dose significantly increased for 1-hour (p < 0.0001) and 2-hour (p < 0.001) but not 4-hour intervals (p = 0.462). C(max) and AUC(0-24) following 8 × 100 μg were approximately fivefold of those following 1 × 100 μg. Dizziness (11.9 percent) and somnolence (4.9 percent) were most common adverse events (AEs). 12.9 percent of patients discontinued due to AEs. FPNS exhibited consistently rapid t(max). When intervals between two doses were shorter, the difference in C(max) between the first and second dose was larger. All regimens of FPNS were well tolerated. Exposure reached a plateau after eight consecutive doses, suggesting potential limited absorption through the nasal mucosa.

Metrics

15 Record Views
1 citations in Scopus

Details

Logo image